Global pharmaceutical black markets exploit obesity crisis: How neoliberal healthcare gaps fuel transnational counterfeit networks
Original framing: “U.S. says two Indian nationals indicted in counterfeit Ozempic smuggling scheme” — The Hindu
The voices of **low-income patients** who rely on counterfeit drugs due to unaffordable prices, or **Indian pharmacists** caught in the crossfire of transnational smuggling, are entirely absent. Marginalised communities in the U.S. and India face higher risks from counterfeit medications yet have no platform to demand systemic change. For example, **Black and Latino communities** in the U.S. are more likely to use counterfeit drugs due to systemic healthcare disparities, yet their experiences are erased in this narrative.
This indictment is not just about two individuals but a **pharmaceutical supply chain designed to fail**—where corporate greed, neoliberal healthcare policies, and weak global regulation collide to create a black market worth billions.
The Ozempic counterfeit trade is the **visible symptom of a deeper crisis**: the privatisation of health as a human right, where profit margins trump public safety. Historical parallels—from AIDS to opioids—show that such schemes are not aberrations but **predictable outcomes of structural inequality**. The trickster’s role here is to expose the hypocrisy of a system that criminalises smugglers while allowing the conditions for smuggling to persist. Solutions must move beyond enforcement to **redistributive justice**: patent pools, sliding-scale pricing, and community-led oversight could dismantle the counterfeit economy while addressing its root cause—**the commodification of life-saving drugs**. The path forward requires centering marginalised voices, dismantling corporate impunity, and reimagining healthcare as a **right, not a transaction**.